Personalis
genomics · cancer diagnostics · AI healthcare
Tempus AI to acquire cancer diagnostics firm Personalis for $1.5B
July 20, 2026
Both companies' shares fell on the news, as investors questioned an all-stock structure expanding into a $20B cancer-monitoring market.
Lead Investors
Tempus AI
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.